Pipeline

Before we create
we listen

Serving multiple
patient needs

Everything we do is driven by patients and what they have to live with. We innovate and refine solutions that can be integrated in a seamless way into patients’ lives.

Program
Pre clinical
Phase 1
Phase 2
Phase 3

CLE-905
M1/M4 muscarinic agonist

CLE-901
Novel NMDA antagonist

1

CLE-100 MDD

Developing a new treatment for patients suffering from Major Depressive Disorder

More Info
2

CLE-905 Schizophrenia

Developing a potent M1/M4 preferential muscarinic agonist for Schizophrenia

More Info
Skip to content